Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Empagliflozin (10mg) + Linagliptin (5mg)
Therapeutic Category
Antidiabetic, Cardiology, ENDOCRINOLOGY and Hormonal range, Endocrinology
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*10
Price
₹130/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Emplozin L 10/5 Tablet is a combination therapy containing Empagliflozin (10mg) and Linagliptin (5mg), designed to provide effective management of type 2 diabetes mellitus. This combination works through complementary mechanisms to help control blood sugar levels and improve overall glycemic control in diabetic patients.
Together, these two drugs target different pathways to manage type 2 diabetes, providing a balanced and effective solution for maintaining blood sugar levels within a healthy range.
Common side effects may include nasopharyngitis, headache, urinary tract infections, and gastrointestinal disturbances. Serious side effects can include dehydration, hypotension, or kidney problems.
Emplozin L 10/5 Tablet is indicated for the management of type 2 diabetes mellitus to improve glycemic control, especially in patients who are unable to achieve adequate control through diet, exercise, and other medications alone.
Consult your doctor before using if you have a history of kidney problems or urinary tract infections. Do not use if pregnant or breastfeeding.
Store in a cool, dry place at room temperature (15°C-30°C), away from light and moisture.
Composition : Bromfenac (0.09% w/v) + Moxifloxacin (0.5% w/v)
Composition : Bromfenac (0.9mg) Eye Drops
Composition : Carboxymethylcellulose (3mg/ml) + Glycerin (10mg/ml) + n-acetylcarnosine (10mg/ml)
Composition : Dexamethasone (0.1% w/v) + Tobramycin (0.3% w/v)
Composition : Fluconazole (0.3% w/v)
Composition : Gatifloxacin (0.3% w/v)
Composition : Ketorolac (0.4% w/v) + Olopatadine (0.1% w/v)
Composition : Ketorolac (0.5% w/v)
Composition : Ketorolac (5% w/v) + Moxifloxacin (0.5% w/v)
Composition : Loteprednol etabonate (0.5% w/v)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This advanced anti-diabetic combination is widely used in type 2 diabetes management, making it a high-demand prescription product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in type 2 diabetes, blood sugar control, insulin resistance management, cardiovascular risk reduction support, and long-term glycemic management. It is commonly prescribed by diabetologists and physicians for comprehensive diabetes care.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Empagliflozin 10mg + Linagliptin 5mg Tablets with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from strong chronic prescription demand, growing diabetic patient populations, repeat monthly therapy usage, and high acceptance in diabetology segments when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this anti-diabetic formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.